Saluda Medical, Inc. (SLD.AX)
ASX · AUD · Healthcare · Medical Devices
A$0.25 (+0.00%) as of
Key statistics
- Market cap
- 63.69M
- Forward P/E
- -0.63
- EPS (TTM)
- -0.8800
- Dividend yield
- 0.00%
- 52-week range
- 0.2500 – 1.9000
- Revenue (TTM)
- 90.17M
- Profit margin
- -165.87%
- Analyst target
- A$1.66
- Volume
- 276.85k
About Saluda Medical, Inc.
Saluda Medical, Inc., a medical device company, develops treatments for chronic neurological conditions in the United States, Australia, Europe, and internationally. The company offers a closed-loop, dose-control platform which senses and measures neural responses to stimulation and automatically adjusts therapy based on real-time neurophysiological feedback. It provides Evoke, an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain, and is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy that senses and measures neural activation to optimize therapy and reduce patient and clinician burden. The company was founded in 2011 and is based in Bloomington, Minnesota.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Bloomington, MN, United States
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.